ArticleAnnals of translational medicine2021

Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.

Shuqiao Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.